Effects of Celecoxib on Electroconvulsive Therapy-Induced Cognitive Impairment in Patients With Major Depressive Disorder: A Pilot, Double-Blind, Placebo-Controlled Trial

Nafiseh Banaha1,2,3, Padideh Ghaeli4,2,4, Abolghasem Yousefi5,2,5, Valentin Artounian2, Mohammad H. Afzali6, Mehdi Ghasemi7

1 School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Psychiatry, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
3 Massachusetts College of Pharmacy and Health Sciences, Worcester, MA 01608, USA
4 Roozbeh Hospital, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
5 Department of Anesthesiology, Amir A’lam Hospital, Tehran University of Medical Sciences, Tehran, Iran
6 Department of Psychiatry, University of Montreal, Montreal, Quebec H3C 3J7, Canada
7 Department of Neurology, Medical School, University of Massachusetts, Worcester, MA 01655, USA

Received: 12 Mar. 2019; Accepted: 28 Aug. 2019

Abstract—Cognitive impairment, an important side effect of electroconvulsive therapy (ECT), may be related to the release of prostaglandins in the brain. Cyclooxygenase-2 (COX-2), constitutively expressed in the CNS, has a functional role in glutamate-mediated learning and memory. The goal of this pilot, double-blind, placebo-controlled trial was to evaluate the effects of the selective COX-2 inhibitor celecoxib on the adverse cognitive effects of ECT. Twenty patients diagnosed with the major depressive disorder for which ECT was indicated as a treatment for their current episode randomly received either celecoxib (200 mg orally twice a day, a total dose of 400 mg/day) or placebo. All patients underwent the same protocol for anesthesia and ECT procedures. The patients received celecoxib or the placebo for the whole period of ECT treatment, starting the day before ECT and continuing until the sixth (last) session of ECT. The Wechsler Mental Scale-III (WMS-III), the Mini-Mental Scale Examination (MMSE), and Stroop Color test were used to assess cognition before the first session and after the first, third and sixth sessions of ECT. Hamilton rating scale for depression was also used for the assessment of depression before and after the trial. Our data showed that celecoxib group did not have significant improvement in cognition based on WMS-III or MMSE scores. There was an improvement in the Stroop Color test but not statistically significant. Our results demonstrated that although celecoxib was well tolerated in patients undergoing ECT, it did not improve related cognitive impairment. Clinical trial registration number: IRCT201201247202N2. CNS, central nervous system; COX-2, Cyclooxygenase-2; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision; ECT, electroconvulsive therapy; ECS, electroconvulsive shocks; HAM-D, Hamilton rating scale for depression; LTP, long term potentiation; MDD, major depressive disorder; MMSE, Mini-Mental State Examination; NSAIDs, nonsteroidal anti-inflammatory drugs; WMS-III, Wechsler Memory Scale-III.

Keywords: Celecoxib; Cognition; Cyclooxygenase-2; Electroconvulsive therapy (ECT); Major depressive disorder; Memory impairment

Introduction

Electroconvulsive therapy (ECT) that induces artificial clinical seizures was first introduced as a treatment for schizophrenia in the 1930s, and soon after, it was considered as a highly effective treatment for major depressive disorder (MDD) and a variety of other psychiatric disorders (1,2). There is a noteworthy volume of information in the literature concerning the effects of ECT on memory and cognition (3). A systematic review of the cognitive adverse effects of ECT has indicated memory impairment as a sub-acute side effect of ECT,
which occurs within 24 hours to 2 weeks after the procedure (4). Anterograde, retrograde, and subjective memories are among the cognitive abilities that could be affected by ECT (2,4). Anterograde amnesia relates to impairment in the acquisition of new skills, whereas retrograde amnesia describes the loss of previously acquired memories (5). Reduction in the score of Mini-Mental State Examination (MMSE) and loss of recalling autobiographical memories are other types of cognitive impairments reported following ECT (6). ECT is associated with greater cognitive impairments when compared with sham ECT (anesthetizing the patient without applying electroshocks and delivering electricity) (7).

There are some reported factors that are related to greater cognitive damage after ECT. For instance, if a patient is more disoriented during acute treatment, she/he is more likely to suffer retrograde amnesia. Moreover, the risk of ECT-induced memory loss increases when patients have pre-existing dementia or other neurological conditions (8). Older patients are more sensitive to adverse cognitive effects of ECT, and these effects last longer in the elderly (9). The molecular mechanisms of ECT-induced cognitive impairments have not been completely elucidated. Cholinergic, (10,11) glutamatergic (12), calcium channels (13), and glucocorticoid mechanisms are among the possibilities (14). Moreover, several studies have reported that electroconvulsive seizures are related to the release of prostaglandins in the brain; thus, ECT can influence inflammatory signaling pathways in the central nervous system (CNS) (15). Cyclooxygenase-2 (COX-2), constitutively expressed in the CNS, has a functional role in glutamate-mediated learning and memory (12,16). Furthermore, memory impairment after ECT may have resulted from glutamatergic excitotoxicity (12,17). An investigation on the saturation of long term potentiation (LTP) suggested COX-2 as one of the major cellular mechanisms that cause learning and memory impairment after repeated ECT (12). It was demonstrated that repeated electroconvulsive shocks (ECS) might induce and saturate LTP, which in turn results in a decreased potential and recruitment of LTP (12). According to these findings, interrupting the mechanisms that up-regulate LTP could protect against ECT-induced amnesia. The selective inhibition of COX-2, but not COX-1, may acutely prohibit the suppression of hippocampal LTP (18).

Therefore, we sought to evaluate the effects of the selective COX-2 inhibitor celecoxib on cognitive impairment related to ECT in patients with MDD. To our knowledge, no placebo-controlled human studies have been done on this subject up to date. Therefore, we conducted the present double-blind, placebo-controlled trial of celecoxib in patients diagnosed with MDD undergoing ECT. Our hypothesis was that celecoxib might have protective/improving effects against ECT-related cognitive impairment in MDD patients.

Materials and Methods

Study design

This prospective, double-blind, placebo-controlled clinical trial was registered at www.irtc.ir with an identifier number of IRCT201201247202N2. Ethical committee approval was obtained from the Tehran University of Medical Sciences (TUMS) before starting the study as per the provision of the Helsinki declaration (2000).

The study setting was the psychiatry department of Roozbeh Hospital, affiliated with TUMS, Tehran, Iran. This is a well-known academic center for the treatment of psychiatric patients in Iran. The criteria for inclusion in the study were a comprehensive psychiatric evaluation in which patients between 20 to 75 years of age met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision (DSM-IV-TR) criteria for MDD for which ECT was indicated as a treatment for their current episode and was admitted to the hospital between August 2010 and January 2012. The severity of the participant’s depression was also determined using the Hamilton Depression Rating Scale (HAMD-D). The HAMD-D is the most widely used physician-administered rating scale for depression. The scale summarizes 17 individual scores to provide a total score that indicates the severity of depression (19). HAMD-D was assessed in study participants before and after the trial. All study participants signed consent forms after the study procedures were explained.

The exclusion criteria included the history of drug abuse, irritable bowel syndrome, diabetes mellitus, renal or hepatic impairment, unstable vascular aneurysm, intracranial hemorrhage or stroke, severe pulmonary conditions, hearing or verbal disorders. Pregnant or lactating women, patients receiving corticosteroids or nonsteroidal anti-inflammatory drugs (NSAIDs), and those who had received ECT within the previous two months were also excluded from the trial. Additionally, the presence of psychotic features or delirium, a category above the American Society of Anesthesiologists class III (ASA class III) were among exclusion criteria.
ECT protocols

Patients underwent a total of 6 ECT sessions every 48 hours, the duration between the first ECT and the fourth ECT was 12 days. They received bilateral ECT by using ThymatronDGx (Somatics INC). All ECT procedures were performed between 7:30 to 9 A.M at Roozbeh hospital. Patients were fasting for at least 8 hours before the ECT procedure. During each ECT procedure, patients were administered 0.5 mg atropine followed by 2-3 mg/kg thiopental intravenously (i.v.); succinylcholine (0.5 mg/kg) was administered as a muscle relaxant after the induction of anesthesia. The stimulus intensity was determined by a dose titration procedure (starting at 25.2 millicoloumb), and the seizure threshold was identified in the first session (20,21). Patients’ ventilation was supported using 100% oxygen by a bag and mask until the resumption of patients’ breath. Electrocardiogram, arterial oxygen saturation (pulse oximetry), noninvasive blood pressure, and heart rate of the patients were monitored continuously during the procedure.

Randomization and treatment

Twenty patients with MDD fulfilled the criteria and completed the study (10 female, ten male; mean ±S.D. age, 34.25±10.18 years). The study participants, who were admitted to receive ECT, were randomized by the research executive manager (one of the investigators) based on a table of random numbers. Accordingly, patients were given celecoxib (200 mg orally twice a day, a total dose of 400 mg per day) or placebo beginning the day before the first session of ECT until the sixth session of ECT. The study patients, the anesthesiologist, the nursing staff, and the rater of the scales were all blind to the treatment assignments. Cognitive improvement was defined based on changes in the scores of MMSE and WMS-III (logical memory, digit span, and associate learning) and reduction of errors in the Stroop Color test. Side effects and tolerability were reported by direct inquiry.

The MMSE is a 12-item test that can be reliably and repeatedly used to screen and monitor cognitive dysfunction in patients undergoing ECT (6,23,24). The highest score in MMSE is 30, with the inversely related to cognitive abnormality. Scores lower than 23 usually indicate some degree of cognitive impairment. The WMS-III has been designed to assess different memory functions in patients between 16-90-year-old with three subscales of logical memory, digit span, and associate learning. (25-27) Higher scores in this test represent a better cognitive function. The Stroop Color Test also assesses the ability to inhibit cognitive interference, which occurs when the processing of a stimulus feature affects the simultaneous processing of another attribute of the same stimulus (28,29).

Statistical analysis

Results are reported as mean±S.D. Data were analyzed using the Statistical Package for the Social Sciences version 19 (IBM SPSS-19). A mixed-design analysis of variance model was employed to examine the between-condition (i.e., celecoxib vs. placebo) differences in repeated measures of depression and neuropsychological scores. Evaluation session (time) was the within-subject factor and condition group (i.e., celecoxib vs. placebo) was the between-subjects factor; the interaction between the treatment group and evaluation session was also included in the model. The violation of equality of covariance matrices and violation of sphericity assumption was verified. In case of the significance of Mauchly's test for sphericity, significance levels of each factor and their interaction was estimated using Greenhouse–Geisser correction. All analyses used the two-tailed significance criteria of P<0.05.
Table 1. Demographic and illness characteristics for patients receiving placebo or celecoxib.

| Demographics                  | Celecoxib group (n=10) | Placebo group (n=10) | t (df) | P    |
|-------------------------------|------------------------|----------------------|--------|------|
| Age                           | Mean: 32.50 S.D: 11.74 | Mean: 36 S.D: 8.628  | 0.57 (18) | 0.46 |
| Education (years)             | 8.90 S.D: 3.40         | 6.80 S.D: 3.800      | 0.76 (18) | 0.21 |
| Age on disease onset          | 28.40 S.D: 11.50       | 29.80 S.D: 11.300    | 0.27 (18) | 0.78 |
| Number of hospitalization     | 1.56 S.D: 1.23         | 0.70 S.D: 0.94       | 1.7 (18)  | 0.11 |
| Gender (female)               | 6 S.D: 60              | 4 S.D: 40            | 0.8 (1)   | 0.37 |
| Marital status                | Single 4 S.D: 40       | Married 4 S.D: 20    | 2.1 (2)   | 0.35 |
| Divorced                      | 2 S.D: 20              | 5 S.D: 50            |          |     |
| Unemployed                    | 6 S.D: 60              | 6 S.D: 60            | 0 (1)     | 1.00 |
| Adverse effects               | 2 S.D: 20              | 1 S.D: 10            | 0.28 (1)  | 0.59 |
| Family history of psychiatric disorders | 30 S.D: 3 | 4 S.D: 4 | 0.4 | 0.76 |

Results

Twenty eligible patients (undergoing ECT therapy) completed the study. Ten patients were assigned to the celecoxib group, and ten patients were assigned to the placebo group. Celecoxib was well tolerated, and no patients withdrew from the study. The demographic characteristic of patients is shown in table 1. There were no significant differences between patients in the duration of depression and the number of previous episodes or comorbid disorders at baseline. Likewise, a comparison of demographic features did not show a significant difference between the two groups. Side effects were generally mild and transient and included stomach upset, headache, heartburn, and nausea.

Table 2 shows the descriptive features of WMS-III, MMSE, and Stroop Color at baseline and after the 1st, 3rd, and sixth sessions of ECT, respectively. For WMS-III logical memory subscale, after Greenhouse–Geisser correction, the linear mixed model showed no significant change in logical memory scores (F(3,54) =0.84, P=0.45) over the course of ECT treatment. The comparison of two treatment conditions does not show a significant between-condition difference for logical memory scores throughout all sessions (F(1,18)=0.57, P=0.46) and no interaction between time and condition (F(3,54) =0.20, P=0.87). For WMS-III digit span subscale, there was no evidence of the violation of the sphericity assumption. The linear mixed model showed no significant change in logical memory scores (F(3,54) =1.56, P=0.21) over the course of ECT treatment. The comparison of two treatment conditions does not show a significant between-condition difference for digit span scores throughout all sessions (F(1,18)=0.26, P=0.61) and no interaction between time and condition (F(3,54) =0.25, P=0.72). For WMS-III associate learning, after Greenhouse–Geisser correction, the linear mixed model showed a significant change in WMS-III scores (F(3,54) =5.17, P=0.009) over the course of ECT treatment. The comparison of two treatment groups shows no significant between-condition difference for WMS-III associate learning scores throughout all sessions (F(1,18)=1.79, P=0.20). However, after correction, the interaction between time and condition was not significant (F(3,54) =0.62, P=0.55). For the Stroop Color outcome, there was no evidence of the violation of the sphericity assumption. The linear mixed model showed a significant change in Stroop Color scores (F(3,54) =7.12, P=0.001) over the course of ECT treatment. The comparison of two treatment conditions does not show a significant between-condition difference for Stroop Color scores throughout all sessions (F(1,18)=0.67, P=0.80) and no interaction between time and condition (F(3,54) =0.29, P=0.84). For the MMSE outcome, after Greenhouse–Geisser correction, the linear mixed model showed no significant change in MMSE scores (F(3,54) =1.46, P=0.241) over the course of ECT treatment. The comparison of two treatment conditions does not show a significant between-condition difference for MMSE scores throughout all sessions (F(1,18)=0.51, P=0.48) and no interaction between time and condition (F(3,54) =0.88, P=0.67). Finally, for the depression outcome, the linear mixed model showed a significant change in HAM-D scores (F(1,18)=36.55, P=0.001) over the course of ECT treatment. The comparison of two treatment conditions does not show a significant between-condition difference for depression scores throughout all sessions (F(1,18)=0.76, P=0.39) and no interaction between time and condition (F(1,18)=0.18, P=0.89).
Discussion

It is well established that ECT can provide rapid, significant improvement in severe symptoms of several psychiatric disorders, including MDD (30). A considerable number of patients undergoing ECT may experience various degrees of cognitive impairment (4). In the present double-blind, placebo-controlled clinical trial, we demonstrated that celecoxib (200 mg orally twice a day) is well tolerated in MDD patients undergoing ECT; however, it did not statistically improve the related cognitive function compared to the placebo group.

To our knowledge, this pilot trial is the first human study that examined the effect of celecoxib on ECT-induced cognitive impairment in MDD patients. The existing evidence in animal studies has demonstrated the effects of COX inhibitors on memory and cognition (12,31-33). The initial investigation by Rao et al., (2002) revealed that 19-day treatment with the non-selective COX inhibitor indomethacin (4 mg/kg/day, oral) attenuated retrograde amnesia induced by two once-daily ECS treatments in rats (34). Considering the fact that COX-2 expression is up-regulated in the microglia of cognitive regions (e.g., hippocampus and cerebral cortex) in patients with Alzheimer's disease (35,36), it is suggested that COX-2 inhibitors may be of therapeutic value in cognitive impairment (37). Selective COX-2 inhibitors have become more available in recent years due to their minimal gastrointestinal adverse effects compared with non-selective COX inhibitors. Accordingly, Andrade et al., (2008) investigated the effects of 8-day oral administration of indomethacin (4 mg/kg/day), celecoxib (15 mg/kg/day), or placebo on ECT-induced retrograde amnesia in rats (12). They found that celecoxib but not indomethacin significantly protected against ECS-induced retrograde amnesia compared with the placebo group (12). In another study, the same group similarly found protective effects of celecoxib (15 mg/kg/day) against ECT-induced memory impairments when it was administered 18 days prior and during ECTs in Wistar rats (31). These pre-clinical data suggest that selective COX-2 inhibitors such as celecoxib could have beneficial effects in improving cognitive impairments induced by ECT.

The mechanisms underlying memory or cognitive impairment due to ECT has not been fully understood. Accumulating evidence suggests a role for glutamatergic neurotransmission in the pathophysiology of memory impairment related to ECT (17,38,39). Glutamatergic system is a key element of LTP and synaptic plasticity

### Table 2. Descriptive features of Wechsler Memory Scale version III (WMS-III), Mini-Mental State Examination (MMSE), and Stroop color at baseline (24 h prior first ECT), 24h after the first, the third, and the sixth (last) ECT session in both placebo and celecoxib groups. Hamilton depression scale (HAM-D) was assessed at baseline (24 h prior first ECT) and 24 hours after sixth (last) ECT

|                      | Celecoxib group (n=10) | Placebo group (n=10) |
|----------------------|------------------------|----------------------|
|                      | Mean                   | S.D.                 |
|                      |                        |                      |
| WMS-L                | Baseline               | 4.3                  | 1.3                  |
| Logical Memory       | 1st ECT                | 4.6                  | 1.72                 |
|                     | 3rd ECT                | 5.2                  | 1.36                 |
|                     | 6th ECT                | 4.9                  | 1.34                 |
| WMS- Digit Span      | Baseline               | 7.4                  | 1.72                 |
|                     | 1st ECT                | 9.0                  | 1.2                  |
|                     | 3rd ECT                | 8.0                  | 2.2                  |
|                     | 6th ECT                | 8.8                  | 2.04                 |
| WMS-Associate Learning | Baseline              | 11.8                 | 2.04                 |
|                     | 1st ECT                | 12.1                 | 3.5                  |
|                     | 3rd ECT                | 12.5                 | 3.3                  |
|                     | 6th ECT                | 13.0                 | 2.8                  |
| Stroop Color         | Baseline               | 8.20                 | 6.48                 |
|                     | 1st ECT                | 7.00                 | 4.90                 |
|                     | 3rd ECT                | 6.00                 | 4.06                 |
|                     | 6th ECT                | 6.00                 | 5.16                 |
| MMSE                 | Baseline               | 26.80                | 2.57                 |
|                     | 1st ECT                | 27.40                | 1.84                 |
|                     | 3rd ECT                | 27.40                | 2.50                 |
|                     | 6th ECT                | 27.70                | 2.36                 |
| HAM-D                | Baseline               | 22.30                | 7.85                 |
|                     | 6th ECT                | 15.60                | 7.85                 |
Celecoxib and cognitive function after ECT

involved in memory and cognitive function (40). Additionally, an investigation on the saturation of LTP suggested COX-2 as one of the major cellular mechanisms that cause learning and memory impairment after repeated ECT (12,31). The above study collected experimental pieces of evidence and demonstrated that repeated ECS might induce and saturate LTP, which in turn results in a decreased potential and recruitment of LTP. Thus, interrupting the mechanisms which up-regulate LTP could protect against ECT-induced amnesia. The selective inhibition of COX-2, but not COX-1, may acutely prohibit the suppression of hippocampal LTP (18), and thereby improving the cognitive function.

While results of clinical studies with COX-2 inhibitors in depression are still absent, clinical improvement of the depressive syndrome has been detected in patients who have been treated with rofecoxib (41). These initial clinical data suggest the therapeutic effects of the selective COX-2 inhibitors in psychiatric disorders, even though these effects should be confirmed in clinical studies on a larger number of MDD patients.

We originally hypothesized that celecoxib might reduce cognitive impairment caused by ECT. However, our data revealed that patients treated with celecoxib did not have any significant improvement in cognitive function as assessed by WMS-III, MMSE, and Stroop Color tests. This end result may be due to the small sample size of this study. Another possibility that the present study did not note much improvement in cognition after the addition of celecoxib to ECT may be due to the fact that the ECT procedure did not produce significant cognitive impairment in this small number of patients. It should be noted that geriatric patients or other patients with high-risk factors for cognitive impairment were not included in this study. Another possibility could be related to the dose of celecoxib (total 400 mg/day) used in this study, as it may have been a relatively low dose to effectively target the cognitive symptoms in these patients.

In summary, although the results of a present double-blind, placebo-controlled clinical trial suggested that celecoxib is well tolerated during ECT therapy in MDD patients, it did not reveal a significant improvement in the ECT-induced cognitive dysfunction in these patients. Further multi-center cohort studies with a larger number of MDD patients and perhaps higher doses of celecoxib are needed to verify the results of the current study.

References

1. Chen P. Optimized treatment strategy for depressive disorder. Advances in Experimental Medicine and Biology 2019; 1180: 201-17.
2. Weiner RD, Reti I.M. Key updates in the clinical application of electroconvulsive therapy. International review of psychiatry (Abingdon, England) 2017; 29: 54-62.
3. Kumar S, Mulsant BH, Liu AY, Blumberger DM, Daskalakis ZJ, Rajji TK. Systematic Review of Cognitive Effects of Electroconvulsive Therapy in Late-Life Depression. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry 2016; 24: 547-65.
4. Andrade C, Arunugham SS, Thirthalli J. Adverse effects of electroconvulsive therapy. Psychiatric Clinics of North America 2016; 39: 513-30.
5. Squire LR. Human memory and amnesia. Neurobiology of learning and memory 1984: 3-64.
6. Abbasinazari M, Adib-Eshgh L, Rostami A, Beyraghi N, Dabir S, Jafari R. Memantine in the prevention or alleviation of electroconvulsive therapy induces cognitive disorders: A placebo controlled trial. Asian journal of psychiatry 2015; 15: 5-9.
7. Vakil E, Grunhaus L., Nagar I, Ben-Chaim E, Dolberg OT, Dannon PN, Schreiber S. The effect of electroconvulsive therapy (ECT) on implicit memory: skill learning and perceptual priming in patients with major depression. Neuropsychologia 2000; 38: 1405-14.
8. Martin DM, Gálvez V, Loo CK. Predicting retrograde autobiographical memory changes following electroconvulsive therapy: relationships between individual, treatment, and early clinical factors. International Journal of Neuropsychopharmacology 2015; 18: pyv067.
9. Geduldig ET, Kellner CH. Electroconvulsive therapy in the elderly: new findings in geriatric depression. Current Psychiatry Reports 2016; 18: 40.
10. Lerer B, Stanley M, McIntyre I, Altman H. Electroconvulsive shock and brain muscarinic receptors: relationship to anterograde amnesia. Life sciences 1984; 35: 2659-2664.
11. Lerer B. Studies on the role of brain cholinergic systems in the therapeutic mechanisms and adverse effects of ECT and lithium. Biological psychiatry 1985; 20: 20-40.
12. Andrade C, Singh NM, Thyagarajan S, Nagaraja N, Sanjay Kumar Rao N, Suresh Chandra J. Possible glutamatergic and lipid signalling mechanisms in ECT-induced retrograde amnesia: experimental evidence for involvement of COX-2, and review of literature. J Psychiat Res 2008; 42: 837-50.
13. Okiyama K, Smith DH, Thomas MJ, McIntosh TK.
Evaluation of a novel calcium channel blocker,(S)-emopamil, on regional cerebral edema and neurobehavioral function after experimental brain injury. Journal of neurosurgery 1992; 77: 607-15.

14. Nagaraja N, Andrade C, Sudha S, Madan Singh N, Chandra JS, Venkataraman B. Glucocorticoid mechanisms may contribute to ECT-induced retrograde amnesia. Psychopharmacology 2007; 190: 73-80.

15. Takemiya T, Matsumura K, Yamagata K. Roles of prostaglandin synthesis in excitotoxic brain diseases. Neurochemistry International 2007; 51 : 112-20.

16. Kanno T, Yaguchi T, Nagata T, Shimizu T, Tanaka A, Nishizaki T. Indomethacin enhances learning and memory potential by interacting with CaMKII. Journal of cellular physiology 2012; 227: 919-26.

17. Chamberlin E, Tsai GE. A glutamatergic model of ECT-induced memory dysfunction. Harvard review of psychiatry 1998; 5: 307-17.

18. Kotilinek LA, Westerman MA, Wang Q, Panizzon K, Lim GP, Simonyi A, Lesne S, Falinska A, Younkin LH, Younkin SG. Cyclooxygenase-2 inhibition improves amyloid-β-mediated suppression of memory and synaptic plasticity. Brain 2008; 131: 651-64.

19. Hamilton M. A rating scale for depression. Journal of neurology, neurosurgery, and psychiatry 1960; 23: 56-62.

20. Ghasemi M, Kazemi MH, Yoosofi A, Ghasemi A, Paragomi P, Amini H, Afzali MH. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry research 2014; 215: 355-61.

21. Haghghi M, Salehi I, Erfani P, Jahangard L, Bajoghli H, Holsober-Trachler E, Brand S. Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only. J Psychiatr Res 2013; 47: 908-15.

22. Mowl a, Mosavinasab M, Pani A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. Journal of clinical psychopharmacology 2007; 27: 67-70.

23. Martin DM, Katalinic N, Ingram A, Schweitzer I, Smith DJ, Hadzi-Pavlovic D, Loo CK. A new early cognitive screening measure to detect cognitive side-effects of electroconvulsive therapy? J Psychiatr Res 2013; 47: 1967-74.

24. Rajkumar AP, Petit CP, Rachana A, Deinde F, Shyamsundar G, Thangadurai P, Jacob KS. Correlates of self-reported, autobiographical, and mini-mental status examination defined memory deficits following electroconvulsive therapy in South India. Asian journal of psychiatry 2018; 34: 47-53.

25. Tulsky DS, Saklofske DH, Chelune GJ, Heaton RK, Ivnik RJ, Bornstein R, Priftiira A, Ledbetter MF. Clinical Interpretation of the WAIS-III and WMS-III (Practical Resources for the Mental Health Professional) 1st ed. Tulsky DS, Saklofske DH, Chelune GJ, Heaton RK, Ivnik RJ, Bornstein R, Priftiira A, Ledbetter MF, editors. San Diego, California, USA, Academic Press; 2003.

26. Tulsky DS. A new look at the WMS-III: new research to guide clinical practice. Journal of clinical and experimental neuropsychology 2004; 26: 453-58.

27. D'Elia L, Satz P, Schretlen D, Wechsler Memory Scale: a critical appraisal of the normative studies. Journal of clinical and experimental neuropsychology 1989; 11: 551-68.

28. Stroop JR. Studies of interference in serial verbal reactions. Journal of Experimental Psychology 1935; 18: 643-62.

29. Scarpina F, Tagini S. The Stroop Color and Word Test. Frontiers in psychology 2017; 8: 557.

30. Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. The journal of ECT 2004; 20: 13.

31. Andrade C, Thyagarajan S, Singh NM, Vinod PS, Sanjay Kumar Rao N, Chandra JS. Celecoxib as an in vivo probe of cyclooxygenase-2 mechanisms underlying retrograde amnesia in an animal model of ECT. Journal of neural transmission (Vienna, Austria : 1996) 2008; 115: 1063-70.

32. Pigot M, Andrade C, Loo C. Pharmacological attenuation of electroconvulsive therapy--induced cognitive deficits: theoretical background and clinical findings. J ECT 2008; 24: 57-67.

33. Tassoni D, Kaur G, Weisinger RS, Sinclair AJ. The role of eicosanoids in the brain. Asia Pacific journal of clinical nutrition 2008; 17 Suppl 1: 220-28.

34. Rao SK, Andrade C, Reddy K, Madappa K, Thyagarajan S, Chandra S. Memory protective effect of indomethacin against electroconvulsive shock-induced retrograde amnesia in rats. Biological psychiatry 2002; 51: 770-773.

35. Rapoport SI. Arachidonic acid and the brain. The Journal of nutrition 2008; 138: 2515-20.

36. Cuello AC, Ferretti MT, Leon WC, Iulita MF, Melis T, Ducatenzeiler A, Bruno MA, Canneva F. Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegenerative diseases 2010; 7: 96-8.

37. Lipsky PE. The clinical potential of cyclooxygenase-2-specific inhibitors. The American journal of medicine 1999; 106: 51s-57s.

38. Dong J, Min S, Wei K, Li P, Cao J, Li Y. Effects of electroconvulsive therapy and propofol on spatial memory and glutamatergic system in hippocampus of depressed
Celecoxib and cognitive function after ECT

rats. The Journal of ECT 2010; 26: 126-30.
39. Koola MM. Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement. The primary care companion for CNS disorders 2018; 20.
40. Wang H, Peng RY. Basic roles of key molecules connected with NMDAR signaling pathway on regulating learning and memory and synaptic plasticity. Military Medical Research 2016; 3: 26.
41. Muller N, Riedel M, Schwarz M. Psychotropic effects of COX-2 inhibitors-a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry 2004; 37: 266-9.